A Targacept (NASDAQ:TRGT) compound developed for potential applications in asthma and type 2 diabetes has mixed mid-stage clinical trial results that show success in asthma but failure in diabetes.
As a result, Targacept will no longer pursue TC-6987 in the diabetes indication. The mixed results come a week after the Winston-Salem, North Carolina company reported the failure of depression drug candidate TC-5214 in the final set of phase 3 studies. In announcing the release of the TC-5214 results, Targacept, which partnered with AstraZeneca (NYSE:AZN) on the development of the compound, said it would cease that development program.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
TC-6987 was studied in two separate exploratory phase 2 studies, one for asthma and another in diabetes. In the asthma study, the compound was better than a placebo at increasing forced expiratory volume — the amount of air a patient can blow out after full inspiration. But in the diabetes study, the compound failed to meet the primary goal of a change in fasting plasma glucose.
Targacept, a spinout company from tobacco giant R.J. Reynolds, develops compounds that have an effect on the body’s neuronal nicotinic receptors. Before TC-5214’s failure in clinical trials, the compound had been Targacept’s lead drug candidate. CEO Don deBethizy said in a statement that the TC-6987 studies accomplished Targacept’s goal of showing the potential of the company’s technology beyond treating central nervous system disorders.
Besides TC-6987, Targacept also has clinical-stage programs in Alzheimer’s disease. Experimental Alzheimer’s disease treatment AZD1446 is currently in a phase 2 clinical trial financed and conducted by AstraZeneca.
[Photo from Flickr user shawnzrossi]